<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p5" style="overflow: hidden; position: relative; background-color: white; width: 1286px; height: 909px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_5{left:89px;bottom:23px;letter-spacing:-0.46px;word-spacing:0.13px;}
#t2_5{left:352px;bottom:29px;}
#t3_5{left:359px;bottom:23px;letter-spacing:-0.03px;}
#t4_5{left:391px;bottom:29px;}
#t5_5{left:396px;bottom:23px;letter-spacing:-0.27px;word-spacing:-0.21px;}
#t6_5{left:558px;bottom:29px;}
#t7_5{left:565px;bottom:23px;letter-spacing:-0.39px;word-spacing:-0.09px;}
#t8_5{left:335px;bottom:836px;letter-spacing:0.22px;word-spacing:-0.51px;}
#t9_5{left:335px;bottom:806px;letter-spacing:0.38px;word-spacing:-0.68px;}
#ta_5{left:1139px;bottom:25px;letter-spacing:-0.05px;}
#tb_5{left:89px;bottom:755px;letter-spacing:-0.08px;word-spacing:-1.02px;}
#tc_5{left:611px;bottom:763px;letter-spacing:-0.17px;}
#td_5{left:89px;bottom:733px;letter-spacing:0.07px;}
#te_5{left:126px;bottom:733px;word-spacing:-1.22px;}
#tf_5{left:335px;bottom:733px;letter-spacing:-0.49px;}
#tg_5{left:366px;bottom:733px;letter-spacing:-0.09px;word-spacing:-1.14px;}
#th_5{left:615px;bottom:733px;letter-spacing:-0.23px;}
#ti_5{left:89px;bottom:710px;letter-spacing:-0.11px;word-spacing:-1.12px;}
#tj_5{left:89px;bottom:688px;letter-spacing:-0.05px;word-spacing:-0.09px;}
#tk_5{left:89px;bottom:665px;letter-spacing:-0.17px;word-spacing:-0.46px;}
#tl_5{left:189px;bottom:672px;letter-spacing:-0.17px;}
#tm_5{left:212px;bottom:665px;letter-spacing:-0.11px;word-spacing:0.09px;}
#tn_5{left:89px;bottom:642px;letter-spacing:-0.03px;word-spacing:-0.22px;}
#to_5{left:89px;bottom:620px;letter-spacing:-0.08px;word-spacing:0.05px;}
#tp_5{left:89px;bottom:597px;letter-spacing:-0.1px;word-spacing:0.08px;}
#tq_5{left:215px;bottom:605px;letter-spacing:-0.17px;}
#tr_5{left:238px;bottom:597px;letter-spacing:-0.18px;word-spacing:0.15px;}
#ts_5{left:89px;bottom:575px;letter-spacing:-0.16px;word-spacing:-0.67px;}
#tt_5{left:216px;bottom:575px;}
#tu_5{left:230px;bottom:575px;letter-spacing:-0.14px;word-spacing:-0.61px;}
#tv_5{left:482px;bottom:575px;}
#tw_5{left:497px;bottom:575px;letter-spacing:0.03px;word-spacing:-0.46px;}
#tx_5{left:89px;bottom:552px;letter-spacing:-0.1px;word-spacing:0.08px;}
#ty_5{left:89px;bottom:529px;letter-spacing:-0.13px;word-spacing:-1.09px;}
#tz_5{left:363px;bottom:537px;letter-spacing:-0.17px;}
#t10_5{left:385px;bottom:529px;letter-spacing:-0.1px;word-spacing:0.07px;}
#t11_5{left:89px;bottom:507px;letter-spacing:-0.12px;word-spacing:-0.94px;}
#t12_5{left:89px;bottom:484px;letter-spacing:-0.06px;word-spacing:0.04px;}
#t13_5{left:414px;bottom:492px;letter-spacing:-0.17px;}
#t14_5{left:436px;bottom:484px;letter-spacing:-0.09px;word-spacing:0.09px;}
#t15_5{left:89px;bottom:462px;letter-spacing:-0.15px;word-spacing:0.12px;}
#t16_5{left:89px;bottom:439px;letter-spacing:-0.15px;word-spacing:-0.32px;}
#t17_5{left:89px;bottom:418px;letter-spacing:-0.07px;word-spacing:0.05px;}
#t18_5{left:89px;bottom:395px;letter-spacing:-0.17px;word-spacing:0.15px;}
#t19_5{left:89px;bottom:372px;letter-spacing:-0.08px;word-spacing:0.06px;}
#t1a_5{left:89px;bottom:350px;letter-spacing:-0.11px;word-spacing:0.1px;}
#t1b_5{left:89px;bottom:327px;letter-spacing:-0.11px;word-spacing:-0.74px;}
#t1c_5{left:89px;bottom:305px;letter-spacing:-0.11px;word-spacing:0.08px;}
#t1d_5{left:176px;bottom:312px;letter-spacing:-0.17px;}
#t1e_5{left:198px;bottom:305px;letter-spacing:-0.08px;word-spacing:0.07px;}
#t1f_5{left:89px;bottom:282px;letter-spacing:-0.17px;word-spacing:0.15px;}
#t1g_5{left:89px;bottom:243px;letter-spacing:-0.11px;word-spacing:-0.85px;}
#t1h_5{left:89px;bottom:220px;letter-spacing:-0.17px;word-spacing:0.15px;}
#t1i_5{left:89px;bottom:198px;letter-spacing:-0.07px;word-spacing:0.06px;}
#t1j_5{left:89px;bottom:175px;letter-spacing:-0.12px;word-spacing:-1.1px;}
#t1k_5{left:89px;bottom:153px;letter-spacing:-0.05px;word-spacing:0.03px;}
#t1l_5{left:89px;bottom:130px;letter-spacing:-0.19px;word-spacing:0.16px;}
#t1m_5{left:89px;bottom:107px;letter-spacing:-0.17px;word-spacing:0.15px;}
#t1n_5{left:656px;bottom:755px;letter-spacing:-0.18px;word-spacing:0.16px;}
#t1o_5{left:656px;bottom:733px;letter-spacing:-0.25px;word-spacing:0.22px;}
#t1p_5{left:1030px;bottom:733px;letter-spacing:-0.01px;word-spacing:-0.01px;}
#t1q_5{left:656px;bottom:710px;letter-spacing:0.05px;}
#t1r_5{left:711px;bottom:710px;letter-spacing:-0.5px;}
#t1s_5{left:742px;bottom:710px;letter-spacing:-0.04px;word-spacing:-1.18px;}
#t1t_5{left:991px;bottom:710px;letter-spacing:-0.03px;word-spacing:0.01px;}
#t1u_5{left:656px;bottom:688px;letter-spacing:-0.09px;word-spacing:-0.33px;}
#t1v_5{left:656px;bottom:665px;letter-spacing:-0.07px;word-spacing:0.04px;}
#t1w_5{left:656px;bottom:642px;letter-spacing:-0.07px;word-spacing:0.04px;}
#t1x_5{left:789px;bottom:650px;letter-spacing:-0.06px;}
#t1y_5{left:833px;bottom:642px;letter-spacing:-0.19px;word-spacing:0.18px;}
#t1z_5{left:656px;bottom:620px;letter-spacing:-0.07px;word-spacing:0.05px;}
#t20_5{left:656px;bottom:597px;letter-spacing:-0.11px;word-spacing:0.1px;}
#t21_5{left:656px;bottom:575px;letter-spacing:-0.1px;word-spacing:-1.12px;}
#t22_5{left:1010px;bottom:582px;}
#t23_5{left:1021px;bottom:575px;letter-spacing:-0.17px;word-spacing:0.15px;}
#t24_5{left:656px;bottom:552px;letter-spacing:-0.11px;word-spacing:0.08px;}
#t25_5{left:656px;bottom:529px;letter-spacing:-0.11px;word-spacing:-1.1px;}
#t26_5{left:656px;bottom:507px;letter-spacing:-0.17px;word-spacing:0.05px;}
#t27_5{left:656px;bottom:484px;letter-spacing:-0.1px;word-spacing:0.08px;}
#t28_5{left:656px;bottom:462px;letter-spacing:-0.06px;word-spacing:0.04px;}
#t29_5{left:656px;bottom:439px;letter-spacing:-0.13px;word-spacing:-1.08px;}
#t2a_5{left:656px;bottom:418px;letter-spacing:-0.19px;word-spacing:-0.57px;}
#t2b_5{left:656px;bottom:395px;letter-spacing:-0.03px;word-spacing:0.01px;}
#t2c_5{left:656px;bottom:372px;letter-spacing:-0.11px;word-spacing:-1.11px;}
#t2d_5{left:656px;bottom:350px;letter-spacing:-0.17px;word-spacing:-0.52px;}
#t2e_5{left:656px;bottom:327px;letter-spacing:-0.12px;word-spacing:0.1px;}
#t2f_5{left:656px;bottom:305px;letter-spacing:-0.05px;word-spacing:-0.44px;}
#t2g_5{left:656px;bottom:282px;letter-spacing:-0.07px;word-spacing:-0.3px;}
#t2h_5{left:656px;bottom:260px;letter-spacing:-0.16px;word-spacing:0.13px;}
#t2i_5{left:842px;bottom:267px;letter-spacing:-0.17px;}
#t2j_5{left:864px;bottom:260px;letter-spacing:0.05px;word-spacing:-0.08px;}
#t2k_5{left:656px;bottom:237px;letter-spacing:-0.12px;word-spacing:-0.69px;}
#t2l_5{left:656px;bottom:214px;letter-spacing:-0.18px;word-spacing:-1.04px;}
#t2m_5{left:656px;bottom:192px;letter-spacing:-0.12px;word-spacing:0.08px;}
#t2n_5{left:859px;bottom:199px;letter-spacing:-0.17px;}
#t2o_5{left:882px;bottom:192px;letter-spacing:-0.08px;word-spacing:0.07px;}
#t2p_5{left:656px;bottom:169px;letter-spacing:-0.15px;word-spacing:0.12px;}
#t2q_5{left:656px;bottom:147px;letter-spacing:-0.09px;word-spacing:0.08px;}
#t2r_5{left:656px;bottom:107px;letter-spacing:-0.05px;word-spacing:-0.08px;}
#t2s_5{left:656px;bottom:85px;letter-spacing:-0.09px;word-spacing:0.06px;}
#t2t_5{left:656px;bottom:62px;word-spacing:-1.21px;}
#t2u_5{left:865px;bottom:62px;letter-spacing:-0.5px;}
#t2v_5{left:897px;bottom:62px;letter-spacing:-0.01px;word-spacing:-0.02px;}
#t2w_5{left:1154px;bottom:62px;word-spacing:0.01px;}
#t2x_5{left:77px;bottom:889px;letter-spacing:0.18px;}

.s0_5{font-size:10px;font-family:ArialMT_5i;color:#000;}
.s1_5{font-size:6px;font-family:ArialMT_5i;color:#000;}
.s2_5{font-size:27px;font-family:Arial-BoldMT_58;color:#000;}
.s3_5{font-size:17px;font-family:Arial-BoldMT_58;color:#000;}
.s4_5{font-size:17px;font-family:ArialMT_5i;color:#000;}
.s5_5{font-size:11px;font-family:ArialMT_5i;color:#000;}
.s6_5{font-size:17px;font-family:Arial-ItalicMT_5n;color:#000;}
.s7_5{font-size:10px;font-family:NimbusSans-Regular_62;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts5" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_58;
	src: url("fonts/Arial-BoldMT_58.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_5n;
	src: url("fonts/Arial-ItalicMT_5n.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5i;
	src: url("fonts/ArialMT_5i.woff") format("woff");
}

@font-face {
	font-family: NimbusSans-Regular_62;
	src: url("fonts/NimbusSans-Regular_62.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg5Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg5" style="-webkit-user-select: none;"><object width="1286" height="909" data="5/5.svg" type="image/svg+xml" id="pdf5" style="width:1286px; height:909px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_5" class="t s0_5">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_5" class="t s1_5">© </span>
<span id="t3_5" class="t s0_5">(NCCN </span>
<span id="t4_5" class="t s1_5">© </span>
<span id="t5_5" class="t s0_5">), All rights reserved. NCCN Guidelines </span>
<span id="t6_5" class="t s1_5">® </span>
<span id="t7_5" class="t s0_5">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_5" class="t s2_5">NCCN Guidelines Version 4.2024 </span>
<span id="t9_5" class="t s2_5">Head and Neck Cancers </span>
<span id="ta_5" class="t s3_5">MS-45 </span>
<span id="tb_5" class="t s4_5">published in 2009 showed that surgery or RT have similar effectiveness </span>
<span id="tc_5" class="t s5_5">573 </span>
<span id="td_5" class="t s4_5">(see </span><span id="te_5" class="t s6_5">Cancer of the Glottic Larynx </span><span id="tf_5" class="t s4_5">and </span><span id="tg_5" class="t s6_5">Cancer of the Supraglottic Larynx </span><span id="th_5" class="t s4_5">in </span>
<span id="ti_5" class="t s4_5">the NCCN Guidelines for Head and Neck Cancers), although the quality of </span>
<span id="tj_5" class="t s4_5">studies comparing the effectiveness of RT and surgery in early laryngeal </span>
<span id="tk_5" class="t s4_5">cancer is low. </span>
<span id="tl_5" class="t s5_5">574 </span>
<span id="tm_5" class="t s4_5">A systematic review including 48 studies of patients with </span>
<span id="tn_5" class="t s4_5">T2 glottic cancer specifically showed no difference in 5-year local control </span>
<span id="to_5" class="t s4_5">between transoral surgery (1156 patients; 77.3%) and EBRT (3191 </span>
<span id="tp_5" class="t s4_5">patients; 75.8%). </span>
<span id="tq_5" class="t s5_5">575 </span>
<span id="tr_5" class="t s4_5">However, a meta-analysis including 11 studies </span>
<span id="ts_5" class="t s4_5">showed that OS (</span><span id="tt_5" class="t s6_5">P </span><span id="tu_5" class="t s4_5">= .04) and laryngeal preservation (</span><span id="tv_5" class="t s6_5">P </span><span id="tw_5" class="t s4_5">&lt; .001) were both </span>
<span id="tx_5" class="t s4_5">better in patients who were treated with transoral laser microsurgery, </span>
<span id="ty_5" class="t s4_5">compared to patients treated with RT. </span>
<span id="tz_5" class="t s5_5">576 </span>
<span id="t10_5" class="t s4_5">The choice of treatment modality </span>
<span id="t11_5" class="t s4_5">depends on anticipated functional outcome, the patient’s wishes, reliability </span>
<span id="t12_5" class="t s4_5">of follow-up, and general medical condition. </span>
<span id="t13_5" class="t s5_5">577 </span>
<span id="t14_5" class="t s4_5">In patients with significant </span>
<span id="t15_5" class="t s4_5">pulmonary comorbidity, total laryngectomy may be preferable over </span>
<span id="t16_5" class="t s4_5">endoscopic or open partial laryngectomy. Partial laryngeal surgery should </span>
<span id="t17_5" class="t s4_5">be carefully considered if adjuvant RT is likely. Consideration should be </span>
<span id="t18_5" class="t s4_5">given to any suspicious lymphadenopathy and risk of metastatic nodal </span>
<span id="t19_5" class="t s4_5">disease. Neck dissection should be performed as indicated when the </span>
<span id="t1a_5" class="t s4_5">primary site is treated surgically. In patients with T1–2 node-negative </span>
<span id="t1b_5" class="t s4_5">cancer of the supraglottic larynx, lymph node dissection is associated with </span>
<span id="t1c_5" class="t s4_5">greater OS. </span>
<span id="t1d_5" class="t s5_5">578 </span>
<span id="t1e_5" class="t s4_5">T1–2 supraglottic cancers have a significant risk of occult </span>
<span id="t1f_5" class="t s4_5">nodal disease at presentation. </span>
<span id="t1g_5" class="t s4_5">Postoperative adjuvant treatment depends on the presence or absence of </span>
<span id="t1h_5" class="t s4_5">adverse pathologic features, such as margin status, nodal staging, and </span>
<span id="t1i_5" class="t s4_5">any extranodal extension. For cancer of the glottic larynx, subglottic </span>
<span id="t1j_5" class="t s4_5">extension is also considered an adverse pathologic feature. In the event of </span>
<span id="t1k_5" class="t s4_5">close or positive margins in organ preservation surgery, re-resection to </span>
<span id="t1l_5" class="t s4_5">negative margins may be considered. This may or may not require a total </span>
<span id="t1m_5" class="t s4_5">laryngectomy to achieve. </span>
<span id="t1n_5" class="t s4_5">Resectable, advanced-stage glottic and supraglottic primaries are usually </span>
<span id="t1o_5" class="t s4_5">managed with a combined modality approach (see </span><span id="t1p_5" class="t s6_5">Cancer of the Glottic </span>
<span id="t1q_5" class="t s6_5">Larynx </span><span id="t1r_5" class="t s4_5">and </span><span id="t1s_5" class="t s6_5">Cancer of the Supraglottic Larynx </span><span id="t1t_5" class="t s4_5">in the NCCN Guidelines for </span>
<span id="t1u_5" class="t s4_5">Head and Neck Cancers). If laryngeal preservation is desired, concurrent </span>
<span id="t1v_5" class="t s4_5">systemic therapy/RT is recommended, based on results from Intergroup </span>
<span id="t1w_5" class="t s4_5">trial RTOG 91-11. </span>
<span id="t1x_5" class="t s5_5">288,294 </span>
<span id="t1y_5" class="t s4_5">R91-11 was a successor trial to the VA trial and </span>
<span id="t1z_5" class="t s4_5">compared three non-surgical regimens: 1) induction cisplatin/5-FU </span>
<span id="t20_5" class="t s4_5">followed by RT (control arm and identical to that in the VA trial); 2) </span>
<span id="t21_5" class="t s4_5">concurrent RT and high-dose cisplatin 100 mg/m </span>
<span id="t22_5" class="t s5_5">2 </span>
<span id="t23_5" class="t s4_5">days 1, 22, and 43; and </span>
<span id="t24_5" class="t s4_5">3) RT alone. RT was uniform in all three arms (70 Gy/7 weeks, 2 </span>
<span id="t25_5" class="t s4_5">Gy/fraction), as was the option of surgery (including total laryngectomy) for </span>
<span id="t26_5" class="t s4_5">relapsed/refractory disease in all arms. Patients with stage III and IV (M0) </span>
<span id="t27_5" class="t s4_5">disease were eligible, excluding T1 primaries and high-volume T4 </span>
<span id="t28_5" class="t s4_5">primaries (tumor extending &gt;1 cm into the base of the tongue or tumor </span>
<span id="t29_5" class="t s4_5">penetrating through cartilage). The key findings of the R91-11 trial were: 1) </span>
<span id="t2a_5" class="t s4_5">a statistically significant higher 2-year laryngeal preservation (local control) </span>
<span id="t2b_5" class="t s4_5">rate of 88% for concurrent RT with cisplatin, compared to 74% for </span>
<span id="t2c_5" class="t s4_5">induction chemotherapy and 69% for RT alone; 2) no significant difference </span>
<span id="t2d_5" class="t s4_5">in laryngeal preservation between induction and RT alone treatments; and </span>
<span id="t2e_5" class="t s4_5">3) similar survival for all treatment groups. Based on these results, </span>
<span id="t2f_5" class="t s4_5">concurrent RT and systemic therapy (cisplatin preferred [category 1]) is a </span>
<span id="t2g_5" class="t s4_5">treatment option for achieving laryngeal preservation for T3, any N glottic </span>
<span id="t2h_5" class="t s4_5">and supraglottic cancers. </span>
<span id="t2i_5" class="t s5_5">294 </span>
<span id="t2j_5" class="t s4_5">Long-term follow-up (10 years) of R91-11 </span>
<span id="t2k_5" class="t s4_5">indicates that laryngeal preservation continues to be better (ie, statistically </span>
<span id="t2l_5" class="t s4_5">different) with concurrent cisplatin/RT when compared with either induction </span>
<span id="t2m_5" class="t s4_5">chemotherapy or RT alone. </span>
<span id="t2n_5" class="t s5_5">288 </span>
<span id="t2o_5" class="t s4_5">OS was not statistically different for all </span>
<span id="t2p_5" class="t s4_5">treatment groups; there was more non–cancer-related mortality among </span>
<span id="t2q_5" class="t s4_5">patients treated with concurrent cisplatin/RT. </span>
<span id="t2r_5" class="t s4_5">Definitive RT (without systemic therapy) is an option for patients with T3, </span>
<span id="t2s_5" class="t s4_5">N0–1 disease who are medically unfit or refuse systemic therapy (see </span>
<span id="t2t_5" class="t s6_5">Cancer of the Glottic Larynx </span><span id="t2u_5" class="t s4_5">and </span><span id="t2v_5" class="t s6_5">Cancer of the Supraglottic Larynx </span><span id="t2w_5" class="t s4_5">in the </span>
<span id="t2x_5" class="t s7_5">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
